Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: Clinical outcomes from a retrospective clinical study

Medical Oncology

Volumn 29, Issue 2, 2012, Pages 750-754

  Kontovinis, Loukas ^a   Laschos, Konstantinos ^b   Karadimou, Alexandra ^c   Andreadis, Charalambos ^a   Bamias, Aristotelis ^c   Paraskevopoulos, Panagiotis ^a   Dimopoulos, Meletios ^c   Papazisis, Konstantinos ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Renal cell cancer; Second line; Sequencing; Sequential use; Sorafenib; Sunitinib; Tyrosine kinase inhibitor

Indexed keywords

ANTIHYPERTENSIVE AGENT; SORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; PYRIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GREECE; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY METASTASIS; MALE; MEDICAL RECORD; MUCOSA INFLAMMATION; MYALGIA; NAUSEA AND VOMITING; OVERALL SURVIVAL; PRIORITY JOURNAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; KIDNEY CARCINOMA; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PYRIDINES; PYRROLES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84866271006     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9815-6     Document Type: Article

References (27)

1. Ferlay J, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-92.
2. Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005;23:202-12.
3. Thompson RH, et al. Renal cell carcinoma in young and old patients-is there a difference? J Urol. 2008;180:1262-6.
4. Escudier B, et al. for the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356:125-34.
5. Escudier B, et al. for the AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-11.
6. Motzer RJ, et al. for the RECORD-1 study group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372: 449-56.
7. Hudes G, et al. Global ARCC trial: temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356:2271-81.
8. Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
9. Sternberg CN, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2010; 28:1061-8.
10. EU SmPC Nexavar. Available at: http://emc.medicines.org.uk/medicine/ 18520/SPC/Nexavar+200mg+film-coated+tablets/(2010). Accessed Aug 2010.
11. EU SmPC Sutent. Available at: http://emc.medicines.org.uk/medicine/18531/ SPC/SUTENT+12.5mg%2c+25mg%2c+37.5mg+and+50mg+Hard+Capsules/(2010) Accessed Jul 2010.
12. EU SmPC Torisel. Available at: http://emc.medicines.org.uk/medicine/ 21260/SPC/TORISEL+25+mg+ml+concentrate+and+diluent+for+solution+for+infusion/ (2010) Accessed Jul 2010.
13. EU SmPC Avastin. Available at: http://emc.medicines.org.uk/medicine/ 15748/SPC/Avastin+25mg+ml+concentrate+for+solution+for+infusion/(2010). Accessed Aug 2010.
14. US PI Votrient. FDA 2009. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2009/022465lbl.pdf (2009). Accessed Jul 2010.
15. EU SmPC Afinitor. Available at: http://emc.medicines.org.uk/medicine/ 22281/SPC/Afinitor+Tablets/(2010) Accessed Jul 2010.
16. Choueiri TK, et al. Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol. 2008;19:viii191. abstract 593P.
17. Dudek AZ, et al. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61-7.
18. Porta C, et al. Retrospective analysis of the sequential use of sorafenib and sunitinib in patients with advanced renal cell carcinoma (RCC). Eur Urol Suppl. 2009;8:183. abstract 252.
19. Sablin MP, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29-34.
20. Tamaskar I, et al. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol. 2008;179:81-6.
21. Richter S, et al. Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie. 2008;31(Suppl. 4): Abstract V684.
22. Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst. 2000; 92:205-16.
23. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc. htm#ctc-40 (2010) Accessed Sep 2010.
24. Karaman MW, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-32.
25. National Comprehensive Cancer network. NCCN clinical practice guidelines in oncology kidney cancer v.2.2009. Available at www.nccn.org (2009) Accessed Jun 2009.
26. Kontovinis LF, et al. Sunitinib treatment for patients with clearcell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer. 2009;9:82.
27. Di Lorenzo G, et al. Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. J Clin Oncol. 2009;27:4469-74.